Information relating to the compensation of Mr. Marc de Garidel, Chairman of the Board of Directors - Global
Skip to main content
Ipsen Home Page
Press shift tab to select search category

Loading...
  • Media  arrow down
    < Back
    • Press Releases
    • Media Statements
    • Media Library
    • Our 2023 Integrated Annual Report is live!

      Featured Image
  • Investors arrow down
      < Back
    • Investors
    • Investors
    • Financial Results
    • Annual Reports and Accounts
    • Corporate News
    • Financial Calendar
    • Investor Events
    • Shareholder Information
    • Regulated Information
    • Key Contacts
  • Partnering
  • Careers arrow down
      < Back
    • Careers
    • Careers
    • Working at Ipsen
    • Culture
  • Press shift tab to select search category

    Loading...
  • English  EN     Français  FR     EN  arrow_down
    • English EN
    • Français FR
  • Global Global
    < Back
    • Global EN FR
    • Annual Report EN FR
    • Americas
    • Asia Pacific
    • Europe
    • United States
    • Brazil
    • Canada
    • Mexico
    • Australia
    • China
    • Singapore
    • South Korea
    • Japan
    • Belgium
    • Ukraine
    • UK
    • Germany
    • France
    • Nordics
    • Greece
    • Italy
    • Netherlands
    • Spain
    • Poland
    • Russia
    • Czech Republic
    • Switzerland
    • Austria
  • Home
  • Companyarrow down
      < Back
    • Company
    • Company
    • Leadership
    • History
    • Fondation Ipsen
  • Sciencearrow down
      < Back
    • Science
    • Science
    • Oncology
    • Rare Disease
    • Neuroscience
    • Products
    • R&D
    • Pipeline
    • Clinical Trials
    • Lay Summaries
  • Sustainabilityarrow down
      < Back
    • Sustainability
    • Sustainability
    • Environment
    • Patients
    • People
    • Governance
    • Our Standards
  • Patientsarrow down
      < Back
    • Patients
    • Patients
    • Together for Oncology
    • Together for Rare Disease
    • Together for Neuroscience
    • Collaborate with us
  • Stories
Back

Post navigation

Previous
Next

Information relating to the compensation of Mr. Marc de Garidel, Chairman of the Board of Directors

Information relating to the compensation of Mr. Marc de Garidel, Chairman of the Board of Directors

- 28 March 2018 - 0 mins read

Post navigation

Previous
Next

Related Documents

  • 2018-03-28-BoD-Compensation-of-Mr-Marc-de-Garidel-ENG   Download  (192 KB)

Related Reports and Accounts

2024 Universal Registration Document
08 April 2025 0 mins read

2024 Universal Registration Document

2023 Integrated Annual Report
11 June 2024 1 mins read

2023 Integrated Annual Report

2023 Universal Registration Document
17 April 2024 1 mins read

2023 Universal Registration Document

Information relating to compensation elements of Mr. David Loew, CEO – 31 May 2023
02 June 2023 0 mins read

Information relating to compensation elements of Mr. David Loew, CEO – 31 May 2023

Compensation policy for corporate officers Combined shareholders’ meeting of 31 May 2023
01 June 2023 0 mins read

Compensation policy for corporate officers Combined shareholders’ meeting of 31 May 2023

2022 Integrated Annual Report
31 May 2023 1 mins read

2022 Integrated Annual Report

Generation Ipsen – for positive change
24 April 2023 1 mins read

Generation Ipsen – for positive change

Ipsen in Brief
24 April 2023 1 mins read

Ipsen in Brief

2022 Universal Registration Document
06 April 2023 1 mins read

2022 Universal Registration Document

Information relating to the compensation elements of Mr. David LOEW, Chief Executive Officer
09 February 2023 0 mins read

Information relating to the compensation elements of Mr. David LOEW, Chief Executive Officer

IPN price

€101.70

 €0.60 (0.59%)

  • Media
  • Investors
  • Partnering
  • Careers
  • Company
  • Sustainability
  • Patients
  • Stories
  • Annual Report
  • Contact us

Latest_Ipsen logo
LinkedIn Facebook Instagram Youtube
  • Terms and Conditions
  • Cookie Policy
  • Global Privacy Policy

© Ipsen Pharma. All rights reserved - 2025

You are now leaving the Ipsen group website. To continue, please click on Continue?

Continue